Skip to main content
. 2021 May 21;16(1):99–106. doi: 10.31616/asj.2020.0283

Fig. 5.

Fig. 5

(A–F) The interleukin-6 (IL-6) responder group had significantly greater rates of leg pain improvement at 2 weeks, 1 month, and 2 months post-administration (*p<0.05) compared with the IL-6 nonresponder group, although the improvement rates for low back pain (LBP) and leg numbness did not differ significantly between the groups at any of the investigated time points. NRS, numeric rating scale; BL, baseline.